Global prevalence and clinical outcomes of tubercular uveitis: a systematic review and meta-analysis |
| |
| Affiliation: | 1. Division of Ophthalmology, St John Eye Hospital/Chris Hani Baragwanath Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, South Africa;2. Department of Pediatrics, Chris Hani Baragwanath Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, South Africa;3. Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit (VIDA), Faculty of Health Sciences, University of the Witwatersrand, South Africa;1. Uveitis Services, Neoretina Eyecare Institute, Hyderabad, India;2. Department of Ophthalmology, Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA;3. Jacobs Retina Center at Shiley Eye Center, University of California, San Diego, La Jolla, CA, USA;4. Department of Ophthalmology and Visual Sciences, Texas Tech University Health Sciences Center, Lubbock, TX, USA;5. Department of Ophthalmology, Advanced Eye Center, PGIMER, Chandigarh, India;6. Retina Services, Neoretina Eyecare Institute, Hyderabad, India;7. Department of Ophthalmology, Duke University School of Medicine, NC, USA;1. MEDCIDS—Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal;2. CINTESIS—Center for Health Technology and Services Research, Porto, Portugal;3. RISE—Health Research Network, Porto, Portugal;4. Department of Ophthalmology, Centro Hospitalar Universitário do Porto, Porto, Portugal;5. Unit of Anatomy, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal;6. Department of Ophthalmology, School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal;7. Department of Ophthalmology, University Hospital Center of S. João, Porto, Portugal;8. Unit of Pharmacology and Therapeutics, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal;9. MedInUP—Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal;1. Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia – Cipto Mangunkusumo Kirana Eye Hospital, Jakarta, Indonesia;2. Department of Immunology, Erasmus Medical Center, Rotterdam, The Netherlands;3. Moorfields Eye Hospital, NHS Foundation Trust, London, UK;4. University College London Institute of Ophthalmology, London, UK;5. Singapore National Eye Centre, Singapore;6. Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore;7. Postgraduate Institute of Medical Education and Research, Chandigarh, India;8. Department of Ophthalmology & Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore;9. Singapore Eye Research Institute, Singapore;10. National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore;11. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore;1. Yong Loo Lin School of Medicine, National University of Singapore, Singapore;2. Department of Ophthalmology, Faculty of Medicine Universitas Indonesia, Indonesia;3. Erasmus Medical Center, Rotterdam, The Netherlands;4. Moorfields Eye Hospital, London, United Kingdom;5. Department of Ophthalmology, Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, MA, United States;6. Myungsung Christian Medical Center (MCM) Eye Unit, MCM General Hospital and Myungsung Medical School, Addis Ababa, Ethiopia;7. Department of Ophthalmology, Addis Ababa University School of Medicine, Addis Ababa, Ethiopia;8. Chest and Allergy Clinic, St Mary''s Hospital, Imperial College Healthcare National Health Service Trust, London, England;9. Advanced Eye Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India;10. National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore;11. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore;12. Singapore Eye Research Institute, Singapore;13. Duke-NUS Medical School, Singapore;1. Cornea and Refractive Surgery Department, Asociación para Evitar la Ceguera en México IAP., Mexico City, Mexico;2. Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico;3. Latin American Network for Research in Eye Diseases-LANRED, Mexico City, Mexico;4. Oncology Unit, Ophthalmology Department, Hospital IV Augusto Hernández Mendoza EsSalud, Ica, Peru;5. Ocular Pathology Laboratory “Dr. José Antonio Avendaño Valdez,” Instituto Nacional de Oftalmología “Dr. Francisco Contreras Campos,” Lima, Peru;6. Ophthalmic Pathology Service, Asociación para Evitar la Ceguera en México, I.A.P., Mexico City, Mexico |
| |
| Abstract: | Tubercular uveitis (TBU) is an inflammation/infection of the eye secondary to Mycobacterium tuberculosis infection. The difficulty in making the diagnosis has resulted in variable prevalence and clinical response rates. We aimed to determine the global prevalence of TBU in uveitis patients stratified by TB high-burden countries (HBCs) and non-HBCs and by geographic regions and the clinical response of TBU to antitubercular treatmentWe performed a systematic review and meta-analysis of TBU studies published in PubMed, Scopus and EMBASE, up to June 30, 2020. A random effects model was used for all meta-analyses. Of 5,018 articles identified, 70 prevalence studies (65,607 uveitis and 3,166 TBU cases) and 18 clinical outcome studies (1,570 TBU cases; 1,304 responded to anti-tubercular therapy [ATT]) were analyzed. The overall weighted prevalence of TBU was 4.0% (95% CI, 3–5); in TB HBCs it was 7.0% (95% CI, 5–11), non-HBCs 3.0% (95% CI, 2–4), and sub-Saharan Africa 11.0% (95% CI, 8–15). The overall weighted clinical response was 82.0% (95% CI, 75–89). Despite the difficulty in diagnosing TBU, the prevalence is expectantly higher in HBCs, and sub-Saharan Africa and the clinical outcome is poor. Standardization of diagnostic criteria and ATT is warranted in future cohort studies. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
